Hallermayr, A.; Steinke-Lange, V.; Vogelsang, H.; Rentsch, M.; de Wit, M.; Haberl, C.; Holinski-Feder, E.; Pickl, J.M.A.
Clinical Validity of Circulating Tumor DNA as Prognostic and Predictive Marker for Personalized Colorectal Cancer Patient Management. Cancers 2022, 14, 851.
https://doi.org/10.3390/cancers14030851
AMA Style
Hallermayr A, Steinke-Lange V, Vogelsang H, Rentsch M, de Wit M, Haberl C, Holinski-Feder E, Pickl JMA.
Clinical Validity of Circulating Tumor DNA as Prognostic and Predictive Marker for Personalized Colorectal Cancer Patient Management. Cancers. 2022; 14(3):851.
https://doi.org/10.3390/cancers14030851
Chicago/Turabian Style
Hallermayr, Ariane, Verena Steinke-Lange, Holger Vogelsang, Markus Rentsch, Maike de Wit, Christopher Haberl, Elke Holinski-Feder, and Julia M. A. Pickl.
2022. "Clinical Validity of Circulating Tumor DNA as Prognostic and Predictive Marker for Personalized Colorectal Cancer Patient Management" Cancers 14, no. 3: 851.
https://doi.org/10.3390/cancers14030851
APA Style
Hallermayr, A., Steinke-Lange, V., Vogelsang, H., Rentsch, M., de Wit, M., Haberl, C., Holinski-Feder, E., & Pickl, J. M. A.
(2022). Clinical Validity of Circulating Tumor DNA as Prognostic and Predictive Marker for Personalized Colorectal Cancer Patient Management. Cancers, 14(3), 851.
https://doi.org/10.3390/cancers14030851